DCHP – Full GRADE evidence profiles

Contents

Service interventions

Collaborative care vs. standard care

Quality assessment	Summary of findings

Appendix 21: Full GRADE evidence profiles

							No of patients		Effect		Quality
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Collaborative care**	**Any standard care**	**Relative (95% CI)**	**Absolute**	
Mortality											
9	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	serious[2]	none	117/1493	121/1506	RR 0.94 (0.74 to 1.19)	5 fewer per 1000 (from 21 fewer to 15 more)	⊕⊕OO LOW
Depression outcome. 1. Non-Response (<50% improvement) - sensitivity analysis - End of treatment											
11	randomised trial	serious[3]	serious[4]	no serious indirectness[5]	no serious imprecision	none	1121/1797	1390/1795	RR 0.82 (0.76 to 0.89)	139 fewer per 1000 (from 85 fewer to 186 fewer)	⊕⊕OO LOW
Depression outcome. 1. Non-Response (<50% improvement) - sensitivity analysis - End of treatment - removing those with >50% drop out											
8	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	782/1322	1016/1330	RR 0.79 (0.73 to 0.85)	160 fewer per 1000 (from 115 fewer to 206 fewer)	⊕⊕⊕⊕ HIGH
Depression outcome 2. Non-remission (scoring above cut off e.g. >7 on HAM-D) - End of treatment											
6	randomised trial	serious[6]	serious[4]	no serious indirectness[5]	no serious imprecision	none	611/1174	763/1174	RR 0.84 (0.73 to 0.96)	104 fewer per 1000 (from 26 fewer to 175 fewer)	⊕⊕OO LOW
Depression outcome 2. Non-remission (scoring above cut off e.g. >7 on HAM-D) - End of treatment - papers with >50% drop out removed											
5	randomised trial	no serious limitations	serious[4]	no serious indirectness	no serious imprecision	none	538/1096	689/1095	RR 0.81 (0.73 to 0.9)	120 fewer per 1000 (from 63 fewer to 170 fewer)	⊕⊕⊕O MODERATE
Depression outcome 3. Diagnosis (at follow up) - End of treatment											
2	randomised	no serious	serious[4]	no serious	serious[2,7]	none	76/163	97/158	RR 0.77	141 fewer per	⊕⊕OO

	trial	limitations		indirectness					(0.54 to 1.1)	1000 (from 282 fewer to 61 more)	LOW
Depression outcome 4.Continuous measures depression rating scale(Change score) - End of treatment (Better indicated by less)											
10	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	1001	968	-	SMD -0.31 (-0.4 to -0.22)	⊕⊕⊕⊕ HIGH
Physical health outcome: 2. Pain intensity (Brief pain inventory, author defined scale) - End of treatment (Better indicated by less)											
3	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[7]	none	725	693	-	SMD -0.15 (-0.25 to -0.04)	⊕⊕⊕O MODERATE
Physical health outcome/ QoL: 1. General physical wellbeing/ functioning (SF-12 physical etc) - End of treatment (Better indicated by less)											
5	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	no serious imprecision	none	941	915	-	SMD -0.26 (-0.35 to -0.17)	⊕⊕⊕O MODERATE
Physical health outcome/ QoL: 2. General physical wellbeing/ functioning (Change scores) - End of treatment (Better indicated by less)											
6	randomised trial	serious[6]	no serious inconsistency	no serious indirectness	no serious imprecision	none	566	584	-	SMD -0.12 (-0.24 to -0.01)	⊕⊕⊕O MODERATE
Quality of Life 1. General QoL scales (Euroqol, 0-10 rating scale etc.) - End of treatment (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[7]	none	484	480	-	SMD -0.14 (-0.27 to -0.01)	⊕⊕⊕O MODERATE
Quality of Life 1. General QoL scales (Euroqol, 0-10 rating scale etc.) - Change score (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2,7]	none	146	189	-	SMD -0.08 (-0.29 to 0.14)	⊕⊕⊕O MODERATE
Service use/ Process of care: 1. Did not receive a consultation / specified number of mental health visits - End of treatment											
3	randomised trial	no serious limitations	serious[4]	serious[5]	no serious imprecision	none	239/428	257/405	RR 0.83 (0.67 to 1.02)	108 fewer per 1000 (from 210 fewer to 13 more)	⊕⊕OO LOW
Service use / Process of care (did not receive psychosocial or pharmacological interventions) - End of treatment											
5	randomised trial	no serious limitations	serious[4]	no serious indirectness[5]	no serious imprecision	none	250/921	485/886	RR 0.5 (0.37 to 0.69)	273 fewer per 1000 (from 170 fewer to 345	⊕⊕⊕O MODERATE

										fewer)	
Treatment acceptability - leaving the study early for any reason - End of treatment											
11	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	serious[2]	none	369/1875	383/1867	RR 0.96 (0.85 to 1.08)	8 fewer per 1000 (from 31 fewer to 16 more)	⊕⊕OO LOW
Satisfaction with service - not satisfied with treatment/care - End of treatment											
3	randomised trial	no serious limitations	no serious inconsistency	serious[8]	no serious imprecision	none	159/403	223/442	RR 0.78 (0.67 to 0.91)	111 fewer per 1000 (from 45 fewer to 167 fewer)	⊕⊕⊕O MODERATE

[1] 2 trials are pre-planned sub-group analyses of a larger RCT
[2] Compatible with benefit and no benefit
[3] 3 trials with >50% drop out not accounted for in the analysis
[4] I-squared >50%
[5] 2 trials did not recruit specifically for comorbid chronic physical health problems
[6] 1 trial with >50% drop out not accounted for in the analysis
[7] Sparse data
[8] 1 trial did not recruit specifically for comorbid chronic physical health problem

Psychiatric liaison vs. standard care

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Psychiatric consultation-liasion**	**control**	**Relative (95% CI)**	**Absolute**	
Mortality											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1,2]	none	22/331	19/338	RR 1.18 (0.65 to 2.14)	10 more per 1000 (from 20 fewer to 64	⊕⊕⊕O MODERATE

										more)	
Depression outcome 1. Diagnosis (at follow up)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1,2]	none	245/331	245/338	RR 1.02 (0.93 to 1.12)	14 more per 1000 (from 51 fewer to 87 more)	⊕⊕⊕O MODERATE
Physical health outcome/ QoL: 1. General physical wellbeing/ functioning (SF-12 physical etc) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1,2]	none	213	237	-	SMD -0.06 (-0.25 to 0.12)	⊕⊕⊕O MODERATE
Treatment acceptability - leaving the study early for any reason											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1,2]	none	57/331	40/338	RR 1.46 (1 to 2.12)	54 more per 1000 (from 0 more to 132 more)	⊕⊕⊕O MODERATE

[1] Sparse data

[2] Compatible with benefit and no benefit

Multidisciplinary teams vs. standard care

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Multidisciplinary secondary mental health care teams**	**control**	**Relative (95% CI)**	**Absolute**	**Quality**
Mortality											
1	randomised trial	no serious limitations	no serious inconsistency	serious[1]	Serious[2,3]	none	4/33	3/36	RR 1.45 (0.35 to	37 more per 1000 (from 54	⊕⊕OO LOW

									6.02)	fewer to 417 more)	
Depression outcome 1. Diagnosis (at follow up)											
1	randomised trial	no serious limitations	no serious inconsistency	serious[1]	serious[2]	none	14/33	25/36	RR 0.61 (0.39 to 0.96)	271 fewer per 1000 (from 28 fewer to 423 fewer)	⊕⊕OO LOW
Depression outcome 2.Continuous measures depression rating scale(Change score) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	serious[1]	serious[2]	none	33	36	-	SMD -1.03 (-1.53 to -0.52)	⊕⊕OO LOW
Treatment acceptability - leaving the study early for any reason											
1	randomised trial	no serious limitations	no serious inconsistency	serious[1]	serious[2,3]	none	4/33	4/36	RR 1.09 (0.3 to 4.01)	10 more per 1000 (from 78 fewer to 334 more)	⊕⊕OO LOW

[1] Participants not specifically recruited for a comorbid physical health problem
[2] Sparse data
[3] Compatible with benefit and no benefit

Psychosocial interventions

Physical activity versus standard care

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		**Quality**
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**physical activity**	**standard care**	**Relative (95% CI)**	**Absolute**	
Depression (end of treatment) (Better indicated by less)											

3	randomised trial	no serious limitations	serious[1]	serious[2]	no serious imprecision	none	220	141	-	SMD -0.58 (-1.2 to 0.05)	⊕⊕OO LOW
Depression (Change score) (Better indicated by less)											
3	randomised trial	no serious limitations	serious[1]	serious[2]	no serious imprecision	none	83	81	-	SMD -0.29 (-0.6 to 0.03)	⊕⊕OO LOW
Non remission (below cut off)											
2	randomised trial	no serious limitations	serious[1]	serious[2]	no serious imprecision	none	17/67	29/72	RR 0.64 (0.31 to 1.3)	145 fewer per 1000 (from 278 fewer to 121 more)	⊕⊕OO LOW
Non remission (6-month follow-up)											
2	randomised trial	no serious limitations	no serious inconsistency	serious[2]	no serious imprecision	none	11/63	27/62	RR 0.4 (0.23 to 0.69)	261 fewer per 1000 (from 135 fewer to 335 fewer)	⊕⊕⊕O MODERATE
Quality of life (end of treatment) (Better indicated by less)											
3	randomised trial	no serious limitations	serious[1]	serious[2]	no serious imprecision	none	220	141	-	SMD -0.62 (-1.28 to 0.03)	⊕⊕OO LOW
Physical health outcomes (end of treatment) - Resting HR (beats/min) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[3]	none	16	10	-	SMD -0.58 (-1.39 to 0.23)	⊕⊕⊕O MODERATE

[1] I sqaured > 50%

[2] Population just below cut-off for depression (for some studies)

[3] Sparse data

Peer (self-help) support

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		**Quality**
No of	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other**	**peer (self-**	**standard**	**Relative**	**Absolute**	

studies						considerations	help) support	care	(95% CI)		
CES-D (end of treatment) (Better indicated by less)											
3	randomised trial	no serious limitations	serious[1]	no serious indirectness	no serious imprecision	none	89	102	-	SMD -0.32 (-0.62 to -0.03)	⊕⊕⊕O MODERATE
CES-D (6 month follow-up) (Better indicated by less)											
3	randomised trial	no serious limitations	serious[1]	no serious indirectness	no serious imprecision	none	94	108	-	SMD -0.19 (-0.74 to 0.37)	⊕⊕⊕O MODERATE
Physical Health Outcomes: HIV-1 RNA viral load - End of treatment (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	63	60	-	SMD 0.26 (-0.09 to 0.62)	⊕⊕⊕O MODERATE
Physical Health Outcomes: HIV-1 RNA viral load - 3-month follow-up (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2,3]	none	62	56	-	SMD 0.17 (-0.2 to 0.53)	⊕⊕⊕O MODERATE

[1] I squared > 50%
[2] Sparse data
[3] Compatible with benefit and no benefit

Peer (self-help) support versus group-based cognitive and behavioural intervention

Quality assessment							Summary of findings				
							No of patients		Effect		
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**peer (self-help) support**	**group-based CBT intervention**	**Relative (95% CI)**	**Absolute**	**Quality**
Depression (end of treatment) (Better indicated by less)											

2	randomised trial	no serious limitations	serious[1]	no serious indirectness	no serious imprecision	none	35	54	-	SMD -0.23 (-0.66 to 0.20)	⊕⊕⊕O MODERATE
Depression (6 month follow-up) (Better indicated by less)											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2,3]	none	38	54	-	SMD -0.34 (-0.76 to 0.08)	⊕⊕⊕O MODERATE

[1] I squared > 50%
[2] Compatible with benefit and no benefit
[3] Sparse data

Self-help intervention based on cognitive and behavioural principles versus standard care

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**CBT based self-help intervention**	**standard care**	**Relative (95% CI)**	**Absolute**	**Quality**
Depression outcome (Better indicated by less)											
3	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	no serious imprecision	none	47	56	-	SMD -0.4 (-0.79 to 0)	⊕⊕⊕O MODERATE
Physical health outcome - Visual Functioning Questionnaire (Better indicated by less)											
1	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	serious[2]	none	12	20	-	MD -7.45 (-18.58 to 3.68)	⊕⊕OO LOW

[1] Only looked at sub-group of depression (in one study) original sample not stratified for depression
[2] Sparse data

Individual-based cognitive and behavioural intervention versus standard care

Quality assessment	**Summary of findings**		
	No of patients	**Effect**	**Quality**

Appendix 21: Full GRADE evidence profiles

No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Individually based CBT	control	Relative (95% CI)	Absolute	
Depression (end of treatment) (Better indicated by less)											
4	randomised trial	no serious limitations	serious[1]	no serious indirectness	no serious imprecision	none	177	161	-	SMD -0.55 (-0.97 to -0.13)	⊕⊕⊕O MODERATE
Non-remission (below cut-off)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	5/33	8/33	RR 0.63 (0.23 to 1.71)	92 fewer per 1000 (from 186 fewer to 172 more)	⊕⊕⊕O MODERATE
Depression (f6-month follow-up) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	122	111	-	SMD -0.07 (-0.33 to 0.18)	⊕⊕⊕O MODERATE
QoL (end of treatment) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	21	16	-	SMD 0.00 (-0.65 to 0.65)	⊕⊕⊕O MODERATE
Physical health outcome - CD4 cell count (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	21	16	-	SMD -0.09 (-0.74 to 0.56)	⊕⊕⊕O MODERATE

[1] I squared = 56.4%

[2] Sparse data

Individual-based cognitive and behavioural intervention versus counselling

Quality assessment							Summary of findings				
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	individually based CBT	counselling	Relative (95% CI)	Absolute	Quality

Depression (end of treatment) (Better indicated by less)											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1]	none	182	182	-	SMD -0.23 (-0.62 to 0.17)	⊕⊕⊕O MODERATE
Depression (end of treatment) - change score (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	20	20	-	SMD 0.30 (-0.32 to 0.92)	⊕⊕⊕O MODERATE
Physical health - CD4 Cell Count (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	13	13	-	SMD -0.34 (-0.44 to 1.11)	⊕⊕⊕O MODERATE

[1] Compatible with benefit and no benefit

[2] Sparse data

Group-based cognitive and behavioural intervention versus standard care

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		**Quality**
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**group-based CBT**	**standard care**	**Relative (95% CI)**	**Absolute**	
Depression (end of treatment) (Better indicated by less)											
9	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	reporting bias[1]	305	275	-	SMD -0.54 (-0.86 to -0.21)	⊕⊕⊕O MODERATE
Depression (follow-up - more than 6-months) (Better indicated by less)											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	149	113	-	SMD -0.17 (-0.42 to 0.07)	⊕⊕⊕O MODERATE
Non remission (below cut off)											

1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[3]	none	8/25	21/27	RR 0.41 (0.22 to 0.75)	459 fewer per 1000 (from 195 fewer to 607 fewer)	⊕⊕⊕O MODERATE
Non response (<50% reduction from baseline)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[3]	none	9/25	19/27	RR 0.51 (0.29 to 0.91)	345 fewer per 1000 (from 63 fewer to 500 fewer)	⊕⊕⊕O MODERATE
QoL - SF-30 (end of treatment) - Physical (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[3]	none	20	28	-	SMD -0.28 (-0.86 to 0.29)	⊕⊕⊕O MODERATE

[1] Possible publication bias
[2] Compatible with benefit and no benefit
[3] Sparse data

Group-based cognitive and behavioural intervention versus other psychosocial interventions (peer support or health education)

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Group-based CBT**	**Other psychosocial interventions**	**Relative (95% CI)**	**Absolute**	**Quality**
Depression (end of treatment) (Better indicated by less)											
5	randomised	no serious	no serious	no serious	serious[1]	none	257	209	-	SMD 0.09 (-0.09	⊕⊕⊕O

	trial	limitations	inconsistency	indirectness						to 0.28)	MODERATE
Depression (follow-up - less than 6-months) (Better indicated by less)											
4	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1]	none	188	132	-	SMD 0.15 (-0.08 to 0.37)	⊕⊕⊕O MODERATE

[1] Compatible with benefit and no benefit

Group existential therapy versus standard care

Quality assessment							**Summary of findings**				
							No of patients		**Effect**		**Quality**
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**group existential therapy**	**standard care**	**Relative (95% CI)**	**Absolute**	
Depression - BDI-21 (end of treatment) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	serious[1]	serious[2,3]	none	40	33	-	SMD 0.03 (-0.43 to 0.49)	⊕⊕OO LOW
Depression - HADS (change score - end of treatment) (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2,3]	none	15	15	-	SMD -0.42 (-1.14 to 0.31)	⊕⊕⊕O MODERATE
Non-remission (still meeting diagnosis of depression) - end of treatment											
1	randomised trial	serious[4]	no serious inconsistency	no serious indirectness	serious[2,3]	none	13/34	12/20	RR 0.64 (0.37 to 1.11)	216 fewer per 1000 (from 378 fewer to 66 more)	⊕⊕OO LOW

[1] Subthreshold depression
[2] Sparse data
[3] Effect compatible with benefit and no benefit
[4] Outcomes reported for a subgroup

Pharmacological Interventions

SSRI vs Placebo

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	SSRIs	Placebo	Relative (95% CI)	Absolute	
Leaving the study early: Any reason											
25	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	no serious imprecision	none	341/1608 (21.2%)	292/1529 (19.1%)	RR 1.1 (0.96 to 1.27)	19 more per 1000 (from 8 fewer to 50 more)	⊕⊕⊕O MODERATE
Leaving the Study early: Lack of efficacy											
4	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	4/178 (2.2%)	11/180 (4.7%)	RR 0.43 (0.16 to 1.16)	25 fewer per 1,000	⊕⊕⊕O MODERATE
Leaving the Study early: Due to adverse events											
11	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	no serious imprecision	none	55/841 (6.5%)	27/820 (3.3%)	RR 1.89 (1.23 to 2.89)	27 more per 1,000	⊕⊕⊕O MODERATE
Depression: 1. Not achieving success/ remission (reaching a specified cut off) - observer rated											
14	randomised trial	serious[1]	no serious inconsistency	no serious indirectness	no serious imprecision	none	355/633 (56.1%)	394/564 (69.9%)	RR 0.81 (0.74 to 0.88)	140 fewer per 1,000	⊕⊕⊕O MODERATE

Depression: 2. Non-response (not achieving 50% reduction from baseline) - patient rated e.g. HADS, BDI											
3	randomised trial	no serious limitations	serious[3]	no serious indirectness	serious[2]	none	65/139 (46.8%)	85/140 (66.7%)	RR 0.73 (0.44 to 1.22)	180 fewer per 1,000	⊕⊕OO LOW
Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAMD, MADRS											
17	randomised trial	serious[1]	serious[3]	no serious indirectness	no serious imprecision	none	328/677 (48.4%)	402/656 (61.3%)	RR 0.83 (0.71 to 0.97)	109 fewer per 1,000	⊕⊕OO LOW
Depression: 3. Patient-rated Continuous measures (Better indicated by less)											
13	randomised trial	serious	no serious inconsistency	no serious indirectness	no serious imprecision	none	468	455	-	SMD -0.17 (-0.3 to -0.04)	⊕⊕⊕O MODERATE
Depression: 4. Observer-rated Continuous measures (Better indicated by less)											
25	randomised trial	serious	serious	no serious indirectness	no serious imprecision	none	1086	1030	-	SMD -0.33 (-0.47 to -0.19)	⊕⊕OO LOW
QoL: 1. continuous measures e.g. SQOLI, FACT-G (Better indicated by less)											
7	randomised trial	serious	no serious inconsistency	no serious indirectness	no serious imprecision	none	263	261	-	SMD -0.27 (-0.44 to -0.1)	⊕⊕⊕O MODERATE
Physical outcome / QoL - General physical functioning/ wellbeing (SF-36 physical component) (Better indicated by less)											
5	randomised trial	serious	no serious inconsistency	no serious indirectness	no serious imprecision	none	168	170	-	SMD 0.02 (-0.19 to 0.23)	⊕⊕⊕O MODERATE

[1] some studies did not clearly report whether double blinded
[2] CIs compatible with benefit and no benefit
[3] I-squared >50%

TCA vs Placebo

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other**	**TCAs**	**Placebo**	**Relative**	**Absolute**	

studies						considerations			(95% CI)		
Leaving the study early: Any reason											
6	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1]	none	40/150 (26.7%)	31/152 (20.4%)	RR 1.33 (0.88 to 2.01)	108 more per 1,000	⊕⊕⊕O MODERATE
Leaving due to adverse events											
5	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	23/118 (19.5%)	12/121 (9.9%)	RR 2.00 (1.06 to 3.78)	111 more per 1,000	⊕⊕⊕⊕ HIGH
Depression: 1. Non-response (<50% improvement) - observer rated											
5	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	45/112 (38.9%)	84/112 (76.5%)	RR 0.53 (0.41 to 0.68)	374 fewer per 1,000	⊕⊕⊕⊕ HIGH
Depression: 2. Non-remission - patient rated											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	very serious[1,2]	none	11/35 (31.4%)	17/40 (47.5%)	RR 0.71 (0.4 to 1.29)	137 fewer per 1,000	⊕⊕OO LOW
Depression: 3. Continuous measures (Change score) - patient rated											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	25	27	-	SMD -0.58 (-1.14 to -0.02)	⊕⊕⊕O MODERATE
Depression: 3. Continuous measures (Change score) - observer rated											
8	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	151	173	-	SMD -0.69 (-0.92 to -0.47)	⊕⊕⊕⊕ HIGH

[1] CIs compatible with benefit and no benefit

[2] two small studies

Mianserin vs Placebo

Quality assessment	Summary of findings

							No of patients		Effect		Quality
No of studies	**Design**	**Limitations**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Mianserin**	**Placebo**	**Relative (95% CI)**	**Absolute**	
Leaving the Study early: Any reason - At end of treatment - Cancer											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	13/64 (20.3%)	30/64 (48.1%)	RR 0.43 (0.25 to 0.75)	274 fewer per 1,000	⊕⊕⊕⊕ HIGH
Leaving the study early due to lack of efficacy - At end of treatment - Cancer											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	2/64 (3.1%)	13/64 (23.1%)	RR 0.18 (0.05 to 0.65)	189 fewer per 1,000	⊕⊕⊕⊕ HIGH
Leaving the Study early: Due to adverse events - At end of treatment - Cancer											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1]	none	2/28 (7.1%)	4/27 (14.8%)	RR 0.48 (0.1 to 2.42)	76 fewer per 1,000	⊕⊕⊕O MODERATE
Depression: 2. Non-response (not achieving 50% reduction from baseline) - observer rated e.g. HAMD, MADRS - At end of treatment - Cancer											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	17/64 (26.6%)	36/64 (57.2%)	RR 0.47 (0.3 to 0.74)	303 fewer per 1,000	⊕⊕⊕O MODERATE
Depression: 3. Patient-rated Continuous measures (Better indicated by less)											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[3]	none	36	37	-	SMD -0.5 (-0.96 to -0.03)	⊕⊕⊕O MODERATE
Depression: 4. Observer-rated Continuous measures - Mean Change - Cancer (Better indicated by less)											
3	randomised trial	no serious limitations	serious[4]	no serious indirectness	no serious imprecision	none	75	75	-	SMD -0.52 (-0.85 to -0.2)	⊕⊕⊕O MODERATE

[1] clear heterogeneity by visual inspection
[2] 2 small studies
[3] 1 small study
[4] No explanation was provided

SSRIs vs TCAs

Quality assessment							Summary of findings				
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Head-to-head SSRI	TCA	Relative (95% CI)	Absolute	Quality
Leaving the study early - any reason											
10	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	no serious imprecision	none	68/355 (19.2%)	84/344 (24.4%)	RR 0.77 (0.58 to 1.01)	83 fewer per 1,000	⊕⊕⊕⊕ HIGH
Leaving study early due to adverse events											
8	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1]	none	30/228 (13.2%)	34/213 (16%)	RR 0.81 (0.52 to 1.27)	55 fewer per 1,000	⊕⊕⊕O MODERATE
Leaving study early due to adverse cardiac events											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	1/41 (2.4%)	7/40 (17.5%)	RR 0.14 (0.02 to 1.08)	150 fewer per 1,000	⊕⊕⊕O MODERATE
Leaving the study early: Due to lack of efficacy - At end of treatment											
1	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[2]	none	2/13 (15.4%)	2/11 (18.2%)	RR 0.85 (0.14 to 5.06)	27 fewer per 1,000	⊕⊕⊕O MODERATE
Depression: 1. Remission (below cut-off)											
5	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious[1]	none	43/87 (48.6%)	34/83 (46%)	RR 1.22 (0.88 to 1.67)	73 more per 1,000	⊕⊕⊕O MODERATE
Depression: 2. Non-response (<50% reduction)											
8	randomised	no serious	no serious	no serious	serious[1]	none	150/311	155/314	RR 0.97	49 fewer per	⊕⊕⊕O

	trial	limitations	inconsistency	indirectness			(48.2%)	(49.4%)	(0.83 to 1.14)	1,000	MODERATE
Depression: 3. Continuous measures - observer rated scales (Better indicated by less)											
9	randomised trial	no serious limitations	serious	no serious indirectness	no serious imprecision	none	241	230	-	SMD 0.04 (-0.14 to 0.22)	⊕⊕⊕O MODERATE
Physical health outcome: 1. MMSE - PD - At end of treatment (Better indicated by less)											
2	randomised trial	no serious limitations	no serious inconsistency	no serious indirectness	serious	none	26	24	-	MD -0.11 (-1.34 to 1.12)	⊕⊕⊕O MODERATE

[1] CIs compatible with benefit and no benefit

[2] Just one study